医药行业研报:吉利德SG联合K药一线治疗PD-L1+ TNBC达到PFS主要终点

太平洋证券股份...
30 May

事件:近日,吉利德宣布III 期ASCENT-04 研究达到了PFS 主要终点。(来源:吉利德,太平洋证券研究院)核心观点:SG(TROP2 ADC)联合K 药一线治疗PD-L1+ TNBC 头对头击败K 药+化疗,PFS 延长具有统计学和临床意义。ASCENT-04/KEYNOTED19是一项全球多中心、开放标签、随机III 期临床试验,入组了443 例未经治疗的不可手术局部晚期或转移性TNBC...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10